Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy
This integrative study combining structural modeling, molecular interaction analysis, and transcriptomic validation confirms EGFR, ALK, KRAS, and PD-1 supports their relevance as clinically actionable and structurally druggable biomarkers in NSCLC. These findings support their continued use in targeted therapy design and precision diagnostics, highlighting nanomaterials as ideal carriers due to their ability to enhance immune checkpoint blockade and drug bioavailability in NSCLC.
Authors
- Wenqing Yan (ORCID: https://orcid.org/0000-0002-5405-4026)
- Yingcai Hong (ORCID: https://orcid.org/0000-0001-5890-9469)
- Haihao Zhu (ORCID: https://orcid.org/0000-0001-9568-916X)
- Hongmei Li (ORCID: https://orcid.org/0000-0003-1981-1893)
- Yingjie Liu (ORCID: https://orcid.org/0000-0001-5391-7996)
- Peng Li (ORCID: https://orcid.org/0000-0001-7984-2486)
Institutions
- Jinan University (CN)
- Southern University of Science and Technology (CN)
- China Railway Shanghai Design Institute Group (China) (CN)
- Chongqing Emergency Medical Center (CN)
- Southern Medical University Shenzhen Hospital (CN)
- Shanghai Clinical Research Center (CN)
- Shenzhen Second People's Hospital (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1649445
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00